MS3 | Execution Planning | Claims Strategy
You have more validated data at MS3 than at any previous point before launch. And you are about to put too much of it in front of a buyer who will use one weak claim to discount everything else on the list.
This is not a rigor problem. It is a selection problem. And the discipline that solves it is older than your NPD process.
Romans had a habit of giving form to things that other cultures left abstract. Virtues, concepts, and standards of conduct became deities with their own identities, their own logic, and their own demands. Disciplina governed military precision. Fides governed the keeping of promises. Veritas governed truth as an obligation, not just a preference. These were not metaphors. They were personifications that Romans took seriously enough to name, depict, and invoke.
Evidentia was the personification of clear demonstration: not argument, not assertion, but the capacity to make something so visible, so precisely shown, that an audience could not look away from the truth of it. Roman advocates and orators invoked her in the same way they invoked other abstract deities: as a standard to meet, not a technique to deploy. The orator who filed twelve claims into a closing gave their opponent twelve places to attack. The one who built everything toward a single irrefutable demonstration gave them none. Evidentia did not work through volume. She worked through selection.
At milestone stage 3 (MS3) of the new product development (NPD) process, the claims that leave your desk are not read by scientist buyers in the way a general audience reads marketing copy. They are tested, immediately and instinctively, against the buyer's own bench experience. Evidentia's standard is not about volume or honesty or validation rigor. It is about whether your single most exposed claim survives contact with the person who knows your application area better than your R&D team does. If it does not, your entire list loses the hearing it needed.
You have more validated data at MS3 than at any previous point in the pre-launch prep. Specificity panels, lot-to-lot consistency results, reference material comparisons, beta-site performance reports from six independent labs. That depth should feel like leverage. For most Product Managers (PMs) focused on RUO life sciences products, it does. And that confidence is exactly where the problem starts.
More validated claims build a stronger commercial position: that is the reasonable premise most PMs bring into MS3. Why would you put forward less than what you can honestly say?
Because your scientist buyer is not applying accumulation logic to your list. They are applying falsification logic. Their entire career has been built on identifying where an assertion breaks. When a principal investigator reads your product page they are not asking which claims are true. They are asking which one they can challenge from their own bench experience.
Find one claim they can knock down from memory, and it does not stop there. Doubt propagates backward. The four claims they might otherwise have accepted now look like they came from the same house that produced the one they already don't trust. You have lost the conversation before your field application scientist (FAS) makes the first call.
Two frameworks are worth keeping distinct here. The claims hierarchy framework is upstream planning: it governs what your evidence portfolio licenses you to say at each stage of your product's commercial life, from beta-attributed launch language through to unqualified performance assertions in the Compounding window. As your evidence matures, that framework expands what you are permitted to claim. Evidentia is the deployment filter you apply every time a claim is about to face a scientist, regardless of which evidence window you are in. A deeper evidence base does not mean more claims in front of your buyer. It means your best claim becomes progressively harder to challenge. The selection discipline described in this post applies at launch with three validated claims and at month twenty-four with thirty. The question it answers is always the same: of everything your evidence currently licenses, what should actually lead?
Your scientist buyer runs a specific reading protocol during active evaluation, whether they are conscious of it or not. For a reagent purchase, a single principal investigator (PI) may move through these steps alone. For a capital equipment decision involving a core facility director, a bioinformatics lead, and a lab manager, different committee members are running different steps simultaneously. The core facility director may have already anchored on your throughput claim while the bioinformatics lead is still testing your data output format against their pipeline requirements. The model below describes the individual cognitive sequence. In multi-stakeholder evaluations, treat it as a map of where different members of the buying committee are at any given point, not a linear path the group travels together.
MS3 Claims Strategy
In multi-stakeholder evaluations, different committee members run different steps simultaneously.
Identify the claim that touches their specialty.
Your weakest claim in their domain will surface first.
Apply bench knowledge against the claim.
Claims disconnected from their workflow fail here, silently.
One credible claim earns provisional trust.
This becomes the lens through which they read the rest.
Trust or doubt spreads to adjacent claims.
One failure discounts the list. One win earns the next read.
You need one claim that survives the Test step in the specific workflow context your target buyer works in. Lead with your most exposed defensible claim - not your most impressive one. Those are rarely the same thing.
Falsification logic applies when a scientist has moved into objective scepticism: actively comparing your product against alternatives and testing every claim against their own expertise. For a deeper treatment of how scientists buy, see Hamid Ghanadan, Not Buying It.
The implication is structural: you need one claim that survives the Test step in the specific workflow context your target buyer works in.
The selection rule is straightforward once you accept the falsification logic. Of every claim your evidence currently licenses, identify the one that sits deepest in your target buyer's specialty. That is the one most likely to surface first in their reading protocol and the one most likely to face the hardest test. If that claim holds, you have earned the right to carry the next one. If it does not hold, no other claim on the list will recover it. Lead with your most exposed defensible claim, not your most impressive one. Those are rarely the same thing.
One qualifier: this falsification dynamic applies when a scientist has moved into what Hamid Ghanadan describes in Not Buying It as objective skepticism: actively comparing your product against alternatives and testing every claim against their own expertise. Earlier, when scientists are scanning for relevance rather than probing for weakness, the selection discipline here does not yet apply. In RUO life sciences those earlier stages are served by peer citations in methods sections, application notes in literature alerts, and collaborator mentions at a key conference. The question this post answers is always the same: of everything your evidence currently licenses, what should actually lead?
Before any claim enters your commercial materials at MS3, run it through these three questions:
Claim selection is not about what you can honestly say. It is about what survives contact with a buyer who is professionally trained not to believe you yet. That applies whether your scientist buyer is a PI evaluating a reagent directly, or an OEM development chemist deciding whether your enzyme antigen belongs in their next diagnostic assay platform.
A practical note on authority: the hardest conversation at the MS3 claims review is not with Legal. Legal asks for justification and accepts a documented rationale. The harder conversation is with a VP of Sales whose Q3 forecast is built around a product narrative that includes the claims you are cutting, and whose reps have been using those claims in the field for weeks. The three-question test gives you the commercial argument: a claim your FAS cannot defend under live questioning destroys more pipeline than one you never deployed. Frame the cut as pipeline protection, not risk avoidance, and you are having a conversation Sales leadership can engage with on their own terms.
Evidentia's standard was never about how much truth you could place in front of an audience. It was about finding the one piece so precisely grounded in what the audience already knew that doubt had nowhere left to stand. Your scientist buyer applies that standard to your product page before your FAS ever gets the meeting. Give them one claim that survives it in the context of their specific work and you earn the right to the next conversation. Give them five that generate unanswered follow-up questions and you have trained them to treat your evidence with caution they will carry into every interaction that follows.
The PM who gets this right at MS3 is not the one who did the most validation work. It is the one who understood which piece of that work was undeniable to the specific person reading it. That is a commercial judgment, not a scientific one. It is yours to make.